Navigation Links
Cambridge-based Ligon Discovery Raises $1M in Seed Funding
Date:11/19/2009

CAMBRIDGE, Mass., Nov. 19 /PRNewswire/ -- Ligon Discovery, Inc., which uses proprietary small molecule microarray technology to find drugs against high-value targets, today announced that it has raised $1M in seed financing led by incTANK Ventures. The company will use the capital to complete its initial discovery campaign that will screen over 100 high-value disease protein targets. With this investment, incTANK Ventures General Partner Christian Bailey joins the board.

Patrick Kleyn PhD, Angela Koehler PhD and Benjamin Ebert MD PhD founded Ligon Discovery with an exclusive license to technology invented at Harvard University and already successfully used to find novel drug compounds at the Broad Institute.

Christian Bailey, General Partner at incTANK Ventures, commented, "Ligon represents a rare combination: although it is an early-stage company, its patented technology has already chalked up some significant drug discovery successes which big pharma companies are now pursuing."

"Ligon's technology has already been used to discover drug compounds against high value targets including protein kinases, histone deacetylases, extracellular growth factors, and transcription factors," said Patrick Kleyn, Ligon's CEO and co-founder. He added, "These compounds were subsequently validated by follow-up assays and results have been published in journals such as Nature, Nature Chemical Biology, and the Journal of the American Chemical Society."

"Ligon is a terrific example of how research at one of Massachusetts' leading academic institutions can be commercialized, leading to new jobs and new therapies that help patients," said Dr. Susan Windham-Bannister, President & CEO of the Massachusetts Life Sciences Center, the agency charged with implementing the state's ten-year, $1 billion Life Sciences Initiative. "Translating research from our world-class colleges and universities into early stage
'/>"/>

SOURCE Ligon Discovery, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
3. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
4. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
5. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
6. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. FASgen Announces New Discovery for Treatment of Stroke
9. Nobel Prize-Winning Discovery
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. FASgen Announces a New Discovery in Obesity Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/15/2012)... 15, 2012  LodgeNet Interactive Corporation (Nasdaq: ... media and connectivity services to hospitality and healthcare ... that it will report its Fourth Quarter and ... Wednesday, February 22, 2012. (Logo:  ... also host a teleconference at 5:00 P.M. Eastern ...
(Date:2/15/2012)... -- The more companies learn about overmolding ... special injection-molding technology to add value to their product ... it lowers total production costs—that,s pretty rare these days. ... a one-shot or two-shot process, a thin layer of ... substrate of the product. This exterior layer is what ...
(Date:2/15/2012)... 2012 Celladon Corporation, a biopharmaceutical ... of innovative treatments for cardiovascular diseases, announced ... million equity financing to advance its lead ... of heart failure. The financing was led ... also included new investors Lundbeckfond Ventures, Novartis ...
Breaking Medicine Technology:LodgeNet Interactive to Report Fourth Quarter and Full Year 2011 Results on February 22nd 2Add Value Through Overmolding 2Add Value Through Overmolding 3Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure 2Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure 3Navy announces 2011 Young Investigator Program Awards 18542 1FDA Panel Examines Possible Links Between Food Dyes ADHD 80561 1FDA Panel Examines Possible Links Between Food Dyes ADHD 80561 2FDA Panel Examines Possible Links Between Food Dyes ADHD 80561 3FDA Panel Examines Possible Links Between Food Dyes ADHD 80561 4Lawsuits Arent Improving Nursing Home Care 3A Study 80559 1Lawsuits Arent Improving Nursing Home Care 3A Study 80559 2Lawsuits Arent Improving Nursing Home Care 3A Study 80559 3Lawsuits Arent Improving Nursing Home Care 3A Study 80559 4
... II Results Published in the Journal of Clinical ... -- Results from a,Phase II study - which ... of the Journal of Clinical Oncology (JCO) and ... <a target="_blank" href=,"http://www.jco.org/">www.jco.org - demonstrate that,ixabepilone, a ...
... BRIDGEWATER, N.J., July 05, 2007 /PRNewswire/ -- ... controlled, open-label, Phase,3 study showed that 77 ... (darunavir) 600 mg tablets with,100 mg ritonavir ... (OBR) of antiretroviral (ARV) agents, reached a,plasma ...
Other Medicine Technology:Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 2Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 3Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8
(Date:2/15/2012)... -- As the Diagnostic and Statistical Manual of Mental ... controversy about psychiatric diagnosis is reaching a fever pitch. ... spectrum disorders and depression, among others, are eliciting great ... as a whole. , "Almost no one likes ... about it," said University of Michigan psychiatrist Randolph Nesse. ...
(Date:2/15/2012)... News) -- About 27 million Americans aged 50 and ... benefit from a hearing aid, a new study finds. ... they,re often not covered by insurance, they don,t receive ... or they consider hearing loss an inevitable part of ... researchers. "There,s still a perception among the public ...
(Date:2/15/2012)... University of Exeter, Peninsula College of Medicine and ... South Western Ambulance Service NHS Foundation Trust (SWASFT) ... Foundation Trust (RD&E) to reduce the time it ... the administration of vital clot-busting drug treatment. , ... for Health Research (NIHR) Peninsula Collaboration for Health, ...
(Date:2/15/2012)... One of the first things people ask new parents ... some immigrant parents, especially South Asians, the question may ... as being significantly underweight, meaning they could be at ... Michael,s Hospital say many of these infants are in ... should not be compared to those of babies of ...
(Date:2/14/2012)... EU legislation has negatively affected the treatment received by ... - 15th February. , The meeting was hosted in ... to raise awareness of the many hurdles faced by ... result of the EU Clinical Trials Directive (CTD). , ... controversial pieces of European legislation related to health since ...
Breaking Medicine News(10 mins):Health News:Psychiatric diagnoses: Why no one is satisfied 2Health News:Millions of Americans Have Untreated Hearing Loss: Study 2Health News:Operational research seeks benefit for stroke victims 2Health News:Operational research seeks benefit for stroke victims 3Health News:Many babies born to immigrants are being labeled too small incorrectly 2Health News:Calls for policy changes as lives put at risk by bureaucracy 2Health News:Calls for policy changes as lives put at risk by bureaucracy 3
... and St Thomas, NHS Foundation Trust is to ... workflow system, further enhancing the Trust,s ability to ... of specialties. The success of replacing tape dictation ... Oncology and Renal has led the Trust to ...
... group of California physicians given financial incentives to ... to embrace an array of changes important to ... issued today. , Measures adopted by medical groups ... as electronic medical records, more closely tracking the ...
... Patient Safety Awareness WeekSOUTH BEND, Ind., March 10 ... Press Ganey Associates, Inc. today released a first-of-its-kind ... the correlation between medical errors and the cultural ... report establishes a baseline for future efforts in ...
... Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ), ... commercializing proprietary product candidates principally for use in ... President and CEO Theodore Schroeder will present the ... at 1:40pm Eastern Time (10:40am Pacific Time) during ...
... Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today ... the Cowen & Company 29th Annual Healthcare Conference on ... The presentation will be webcast from the Boston ... via the Web, please go to the Investor Relations ...
... Amgen (Nasdaq: AMGN ) will present ... March 11, 2009 at the Loews Miami Beach Hotel, ... Amgen,s Chief Financial Officer Robert A. Bradway will ... over the Internet and can be accessed from Amgen,s ...
Other Medicine News:Health News:Guy's and St Thomas' NHS Foundation Trust extends patient care benefits of BigHand Digital Dictation 2Health News:Study finds pay for performance stimulates changes in medical practice 2Health News:Study finds pay for performance stimulates changes in medical practice 3Health News:Press Ganey Releases Innovative Report to Assess Culture of Safety in U.S. Hospitals 2Health News:Press Ganey Releases Innovative Report to Assess Culture of Safety in U.S. Hospitals 3Health News:Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Cowen & Company's 29th Annual Health Care Conference in Boston on March 16, 2009 2Health News:Alexza's Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference 2Health News:Alexza's Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference 3
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
... bags are part of the Freedom ... of leg bags, kits, and accessories ... of our customers. These leg bags ... constructed of 100% latex-free soft, textured ...
... It's easy on delicate ... design and hydrophilic coating provide ... lubricating gel. It's easy to ... the catheter with its own ...
... part of the Freedom Urinary Collection ... bags, kits, and accessories designed to ... customers. These leg bags are offered ... 100% latex-free soft, textured medical grade ...
Medicine Products: